Skip to main content

O FUCOSILACION DE PROTEINAS BUSCANDO INHIBIDORES PARA LA LEUCEMIA LINFATICA CELULAR AGUDA Y PARA LA ESCLEROSIS MULTIPLE.

BFU2010-19504

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The mechanism of allosteric coupling in choline kinase α1 revealed by the action of a rationally designed inhibitor

  • Sahún-Roncero, M.
  • Rubio-Ruiz, B.
  • Saladino, Giorgio
  • Conejo-García, A.
  • Espinosa, Antonio
  • Velázquez-Campoy, Adrián
  • Gervasio, Francesco Luigi
  • Entrena, Antonio
  • Hurtado-Guerrero, Ramón
5 pags, 4 pags. -- Supporting information for this article (experimental details) is available on the WWW under http://dx.doi.org/10.1002/anie.201209660., Applying a CHOK hold: Combined experimental and computational studies of the binding mode of a rationally designed inhibitor of the dimeric choline kinase α1 (CHOKα1) explain the molecular mechanism of negative cooperativity (see scheme) and how the monomers are connected. The results give insight into how the symmetry of the dimer can be partially conserved despite a lack of conservation in the static crystal structures. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim., We thank the Fundación Agencia Aragonesa para la Investigación y el Desarrollo (ARAID, Spain), the Ministerio de Economía y Competitividad (MEC, Spain, grants BFU2010-19504, BFU2010-19451, SAF2009-11955, and BIO2010-20166), the Consejería de Innovación, Ciencia y Empresa of the Junta de Andalucía (grant P07-CTS-03210), the Ministerio de Educación for a FPU fellowship (AP2007-03115) to B.R.-R., and Diputación General de Aragón (Grupo Protein Targets, B89) and the Comunidad Autónoma de Madrid S2010-BMD-2457 (BIPEDD2). This work was granted access to the HPC resources of HECToR, within the Distributed European Computing Initiative (FP7/2007-2013, RI-283493).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recent progress on fucosyltransferase inhibitors

  • Merino, Pedro
  • Tejero, Tomás
  • Delso, J. Ignacio
  • Hurtado-Guerrero, Ramón
  • Gómez-SanJuan, Asier
  • Sádaba, David
Fucosyltransferases (FucTs) are enzymes that transfer L-fucose from GDP-fucose to a glycoside or a peptide. They have important roles in a variety of diseases including cancer and autoimmune disorders, viral and bacterial infections and inflammatory processes, and thus they represent important drug targets for the development of agents for the treatment of such disorders. This review highlights recent developments regarding carbohydrate mimics as inhibitors of FucTs. The most recent and relevant synthetic strategies are described., We thank the Spanish Ministry of Science and Innovation (MICINN, Madrid, Spain. Projects CTQ2010-19606 and BFU2010-19504), Feder Program (UE) and The Government of Aragon (Zaragoza, Aragon, Spain, Group E-10) for their support. R. H-G. thanks ARAI+D Program (Government of Aragon) for a permanent position. D.S. thanks CSIC for a pre-doctoral grand (JAE-Pre program). A. G-SJ. acknowledges a post-doctoral contract from project CTQ2010-19606 (MICINN, Madrid, Spain)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase a1 (ChoKa1)

  • Schiaffino-Ortega, S.
  • Baglioni, E.
  • Mariotto, E.
  • Bortolozzi, R.
  • Serrán-Aguilera, L.
  • Riós-Marco, P.
  • Carrasco-Jimenez, M.
  • Gallo, M.A.
  • Hurtado-Guerrero, R.
  • Marco, C.
  • Basso, G.
  • Viola, G.
  • Entrena, A.
  • López-Cara, L.C.
A novel family of compounds derivative of 1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))-bispyridinium or-bisquinolinium bromide (10a-l) containing a pair of oxygen atoms in the spacer of the linker between the biscationic moieties, were synthesized and evaluated as inhibitors of choline kinase against a panel of cancer-cell lines. The most promising compounds in this series were 1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridinium) bromide (10a) and 1,1'-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene))-bis(7-chloro-4-(pyrrolidin-1-yl)quinolinium) bromide (10l), which inhibit human choline kinase (ChoKa1) with IC 50 of 1.0 and 0.92 Î 1/4M, respectively, in a range similar to that of the previously reported biscationic compounds MN58b and RSM932A. Our compounds show greater antiproliferative activities than do the reference compounds, with unprecedented values of GI 50 in the nanomolar range for several of the cancer-cell lines assayed, and more importantly they present low toxicity in non-tumoral cell lines, suggesting a cancer-cell-selective antiproliferative activity. Docking studies predict that the compounds interact with the choline-binding site in agreement with the binding mode of most previously reported biscationic compounds. Moreover, the crystal structure of ChoKa1 with compound 10a reveals that this compound binds to the choline-binding site and mimics HC-3 binding mode as never before.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Pharmacophore-Based Virtual Screening to Discover New Active Compounds for Human Choline Kinase a1

  • Serrán-Aguilera, L.
  • Nuti, R.
  • Lõpez-Cara, L.C.
  • Mezo, M.Á.G.
  • Macchiarulo, A.
  • Entrena, A.
  • Hurtado-Guerrero, R.
Choline kinase (CK) catalyses the transfer of the ATP gamma-phosphate to choline to generate phosphocholine and ADP in the presence of magnesium leading to the synthesis of phosphatidylcholine. Of the three isoforms of CK described in humans, only the a isoforms (HsCK alpha) are strongly associated with cancer and have been validated as drug targets to treat this disease. Over the years, a large number of Hemicholinium-3 (HC-3)-based HsCK alpha biscationic inhibitors have been developed though the relevant common features important for the biological function have not been defined. Here, selecting a large number of previous HC-3-based inhibitors, we discover through computational studies a pharmacophore model formed by five moieties that are included in the 1-benzyl-4-(N-methylaniline) pyridinium fragment. Using a pharmacophore-guided virtual screening, we then identified 6 molecules that showed binding affinities in the low mM range to HsCK alpha 1. Finally, protein crystallization studies suggested that one of these molecules is bound to the choline and ATP-binding sites. In conclusion, we have developed a pharmacophore model that not only allowed us to dissect the structural important features of the previous HC-3 derivatives, but also enabled the identification of novel chemical tools with good ligand efficiencies to investigate the biological functions of HsCK alpha 1.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Streptococcus pneumoniae TIGR4 flavodoxin: Structural and biophysical characterization of a novel drug target

  • Rodríguez-Cardenas, Á.
  • Rojas, A.L.
  • Conde-Giménez, M.
  • Velazquez-Campoy, A.
  • Hurtado-Guerrero, R.
  • Sancho, J.
Streptococcus pneumoniae (Sp) strain TIGR4 is a virulent, encapsulated serotype that causes bacteremia, otitis media, meningitis and pneumonia. Increased bacterial resistance and limited efficacy of the available vaccine to some serotypes complicate the treatment of diseases associated to this microorganism. Flavodoxins are bacterial proteins involved in several important metabolic pathways. The Sp flavodoxin (Spfld) gene was recently reported to be essential for the establishment of meningitis in a rat model, which makes SpFld a potential drug target. To facilitate future pharmacological studies, we have cloned and expressed SpFld in E. coli and we have performed an extensive structural and biochemical characterization of both the apo form and its active complex with the FMN cofactor. SpFld is a short-chain flavodoxin containing 146 residues. Unlike the well-characterized long-chain apoflavodoxins, the Sp apoprotein displays a simple two-state thermal unfolding equilibrium and binds FMN with moderate affinity. The X-ray structures of the apo and holo forms of SpFld differ at the FMN binding site, where substantial rearrangement of residues at the 91-100 loop occurs to permit cofactor binding. This work will set up the basis for future studies aiming at discovering new potential drugs to treat S. pneumoniae diseases through the inhibition of SpFld.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Dynamic interplay between catalytic and lectin domains of GalNAc-transferases modulates protein O-glycosylation

  • Lira-Navarrete, E.
  • Rivas, M.de las
  • Compañón, I.
  • Pallarés, M.C.
  • Kong, Y.
  • Iglesias-Fernández, J.
  • Bernardes, G.J.L.
  • Peregrina, J.M.
  • Rovira, C.
  • Bernadó, P.
  • Bruscolini, P.
  • Clausen, H.
  • Lostao, A.
  • Corzana, F.
  • Hurtado-Guerrero, R.
Protein O-glycosylation is controlled by polypeptide GalNAc-transferases (GalNAc-Ts) that uniquely feature both a catalytic and lectin domain. The underlying molecular basis of how the lectin domains of GalNAc-Ts contribute to glycopeptide specificity and catalysis remains unclear. Here we present the first crystal structures of complexes of GalNAc-T2 with glycopeptides that together with enhanced sampling molecular dynamics simulations demonstrate a cooperative mechanism by which the lectin domain enables free acceptor sites binding of glycopeptides into the catalytic domain. Atomic force microscopy and small-angle X-ray scattering experiments further reveal a dynamic conformational landscape of GalNAc-T2 and a prominent role of compact structures that are both required for efficient catalysis. Our model indicates that the activity profile of GalNAc-T2 is dictated by conformational heterogeneity and relies on a flexible linker located between the catalytic and the lectin domains. Our results also shed light on how GalNAc-Ts generate dense decoration of proteins with O-glycans.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

A proactive role of water molecules in acceptor recognition by protein O-fucosyltransferase 2

  • Valero-González, J.
  • Leonhard-Melief, C.
  • Lira-Navarrete, E.
  • Jiménez-Osés, G.
  • Hernández-Ruiz, C.
  • Pallarés, M.C.
  • Yruela, I.
  • Vasudevan, D.
  • Lostao, A.
  • Corzana, F.
  • Takeuchi, H.
  • Haltiwanger, R.S.
  • Hurtado-Guerrero, R.
Protein O-fucosyltransferase 2 (POFUT2) is an essential enzyme that fucosylates serine and threonine residues of folded thrombospondin type 1 repeats (TSRs). To date, the mechanism by which this enzyme recognizes very dissimilar TSRs has been unclear. By engineering a fusion protein, we report the crystal structure of Caenorhabditis elegans POFUT2 (CePOFUT2) in complex with GDP and human TSR1 that suggests an inverting mechanism for fucose transfer assisted by a catalytic base and shows that nearly half of the TSR1 is embraced by CePOFUT2. A small number of direct interactions and a large network of water molecules maintain the complex. Site-directed mutagenesis demonstrates that POFUT2 fucosylates threonine preferentially over serine and relies on folded TSRs containing the minimal consensus sequence C-X-X-S/T-C. Crystallographic and mutagenesis data, together with atomic-level simulations, uncover a binding mechanism by which POFUT2 promiscuously recognizes the structural fingerprint of poorly homologous TSRs through a dynamic network of water-mediated interactions.